SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense volatility and trading volume as community members debate whether the rally is a legitimate breakout driven by upcoming music festival partnerships or a manipulated pump-and-dump scheme. Investors remain sharply divided, with some highlighting the project's real-world event utility and future roadmap as catalysts for growth, while others express concerns over high wallet concentration and potential regulatory investigation.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is generating significant community buzz as traders weigh its potential as an undervalued DeFi leader against broader market volatility and governance-related news. While some participants are actively accumulating on dips in anticipation of a parabolic breakout, others remain focused on technical support levels and ongoing debates regarding its long-term stability compared to other lending protocols.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining significant traction as investors reconnect with its 2011 origin as the original parody token, with community members highlighting its deep historical roots, locked supply, and organic narrative as drivers for potential long-term growth. While some skeptics dismiss it as a joke, proponents are actively comparing it to early memecoin successes and emphasizing its status as a foundational piece of crypto culture that is currently undergoing a massive resurgence.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining community traction as investors highlight its position in pre-IPO exposure and long-term potential within the AI crypto sector. Discussions emphasize its micro-cap status and emerging utility as a speculative alternative to established AI-focused projects.

Daddy Darth Vader

The community is engaged in a speculative "Daddy Wars" narrative involving DARTH, SIDIOUS, and MAULCOIN, with participants actively debating the leadership and future trajectory of these low market cap tokens. Supporters are highlighting aggressive community-driven marketing and token giveaways, while skeptics warn of volatility and the risks inherent in such nano-cap assets.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a major breakout, driven by the token's cybersecurity utility and its low-float, supply-constrained profile. Traders are actively debating accumulation strategies and sharing bullish sentiment regarding potential partnerships and the broader altcoin market cycle.

Procure ETF Trust II - Procure Space ETF

Procure Space ETF (UFO) is gaining significant traction as investors anticipate the impact of high-profile space sector developments, including the upcoming SpaceX IPO. The community is actively discussing the fund's role as a balanced vehicle for broad space economy exposure compared to picking individual stocks like Rocket Lab or AST SpaceMobile.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Twist Bioscience is generating strong buzz as investors weigh its robust revenue growth and expanding market reach against skepticism regarding the firm's path to consistent profitability. The community is actively debating the company's long-term potential as a foundational "picks and shovels" provider for the biotechnology sector while closely monitoring insider trading activity and recent revenue guidance upgrades.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a significant policy shift following a new executive order that accelerates FDA review pathways for psychedelic-based therapies, including LSD. Investors are actively debating the potential for a sector-wide re-rating and identifying candidates for future M&A, as Definium remains in focus with multiple Phase 3 trial readouts scheduled throughout the year.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum is capturing market attention as a low-float, software-focused quantum computing play that investors are comparing to early-stage operating system developers. Community discussion is centered on its strategic partnerships with major industry players and its potential to benefit from a rotation of liquidity into the quantum sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Growth in Short Interest

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 703,646...

Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Bright Minds Biosciences in a research note on Monday. They set a "buy" rating and a $145.00 price objective for the company...

Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why

Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Should You Buy...

Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% Higher - What's Next?

Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.4% - Here's Why...

Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $147.00 target price on shares of Bright Minds Biosciences in a research note on Monday...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One...

Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Bright Minds Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

303,685 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Braidwell LP

Braidwell LP acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional...

Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright boosted their price objective on Bright Minds Biosciences from $115.00 to $145.00 and gave the stock a "buy" rating in a report on Wednesday...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Current Price	$89.90
Prev Close	$88.65
Open	$91.00
Dividend Yield	N/A
50-Day Moving Average	$78.71
Beta	1.02
Avg. Volume	146,482.92
PE Ratio	-46.35

52-Week High	$123.75
52-Week Low	$23.18
Market Capitalization	$879.87M
EPS (Annual)	-$1.27
Price to Book	10.75
Revenue Per Employee	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRUG News

DRUGBright Minds Biosciences Inc